The goal is to produce tangible research results leading to pre-clinical trials.
The NIH Director’s New Innovator Award is designed “to support exceptionally creative new investigators who propose highly innovative projects that have the potential for unusually high impact.
“This is the kind of award that really highlights the kind of innovative work being done at a cancer center,” said Dr. Samir N. Khleif, Director of the GRU Cancer Center. “This is significant both in terms of furthering Dr. Ande’s work and continuing to drive the GRU Cancer Center toward a position of national prominence.”
Dr. Ande is a member of the GRU Cancer Center’s Molecular Oncology and Biomarkers program and an Assistant Professor of Biochemistry and Molecular Biology. He was recruited to the GRU Cancer Center in May 2013 from the University of Texas Medical Branch.
The GRU Cancer Center is a multi-disciplinary academic cancer center focused on both research and clinical treatment. Its patient-centered approach to treatment includes first-in-the-nation treatment protocols, an experimental therapeutics program that includes specialized clinics for Phase I trials and immunotherapy and a variety of ancillary programs – including music therapy and genetic counseling – designed with holistic healing in mind.